Argos Therapeutics, Inc. (NASDAQ:ARGS) shares gapped up before the market opened on Thursday . The stock had previously closed at $0.17, but opened at $0.18. Argos Therapeutics shares last traded at $0.20, with a volume of 10016770 shares trading hands.

Separately, Zacks Investment Research downgraded shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $4.13.

The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.

An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new stake in shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned 1.21% of Argos Therapeutics at the end of the most recent quarter. 28.22% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/18/argos-therapeutics-inc-args-shares-gap-up-to-0-18.html.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.